A NEW MANUFACTURING APPROACH TO ADCS.

Lock Release, the proprietary technology by ADC Bio, has the potential to consolidate indirect costs and resource hours associated with monoclonal antibodies manufacturing and bioconjugation, writes CEO, Charlie Johnson.